Novartis (NVS) gained 33.73% over the past year, closing at $150.45 on May 20, 2026, amid strong fund positioning.
Novartis AG (NYSE:NVS) emerged as a top contributor in the Loomis Sayles Global Growth Fund’s Q1 2026 investor letter, closing at $150.45 per share on May 20. The stock delivered a 2.01% one-month return and a 33.73% gain over the past 52 weeks, outperforming broader market trends.
The fund, which reported a -13.09% return for Q1 2026, underperformed the MSCI ACWI Index Net’s -3.20% decline. Despite the overall lag, Novartis’s market leadership in branded pharmaceuticals across multiple treatment areas was cited as a key driver of its strong performance. The company holds a market capitalization of $287.07 billion.
Loomis Sayles maintained a long-term strategy focused on high-quality businesses with sustainable competitive advantages, positioning Novartis as a core holding for growth potential in 2026.